Indications of the Italian Association for the Study of the Liver (AISF) on the use of triple therapy (Interferon-pegylated alpha + Ribavirin + first generation protease inhibitors) for the treatment of patients with chronic HCV genotype 1 infection ″ – UPDATE 2013
AISF - ASSOCIAZIONE ITALIANA STUDIO DEL FEGATO → News → GUIDELINES AND POSITION PAPERS HIGHLIGHTS → Indications of the Italian Association for the Study of the Liver (AISF) on the use of triple therapy (Interferon-pegylated alpha + Ribavirin + first generation protease inhibitors) for the treatment of patients with chronic HCV genotype 1 infection ″ – UPDATE 2013
Indications of the Italian Association for the Study of the Liver (AISF) on the use of triple therapy (Interferon-pegylated alpha + Ribavirin + first generation protease inhibitors) for the treatment of patients with chronic HCV genotype 1 infection ″ – UPDATE 2013
